Table 1 Patient and tumor characteristics
|  | All patients (n = 30) | Castrate-resistant (n = 11) | Castrate-sensitive (n = 19) |
|---|---|---|---|
Age, years Median (range) | 71 (56–83) | 72 (56–83) | 69 (57–80) |
Pre-salvage PSA, ng/ml Median (range) | 3.63 (0.05–77) | 3.16 (0.05–12.8) | 4.1 (0.65–77) |
Pre-salvage imaging, n (%) | Â | Â | |
Ga68 PSMA PET | 30 (100%) | 11 (100%) | 19 (100%) |
mpMRI | 11 (37%) | 4 (36%) | 7 (37%) |
Location of local recurrence, n (%) | Â | Â | |
Prostate-only | 18 (60%) | 8 (73%) | 10 (53%) |
Prostate and SV | 10 (33%) | 3 (27%) | 7 (37%) |
SV-only | 2 (7%) | 0 (0%) | 2 (11%) |
Staging at recurrence, n (%) | Â | Â | |
T-stage ≥ T3 (locally advanced) | 14 (47%) | 6 (55%) | 8 (42%) |
Node positive (regional) | 7 (23%) | 3 (27%) | 4 (21%) |
Oligo-metastatic | 1 (3%) | 1 (9%) | 0 (0%) |
Histologic confirmation, n (%) | Â | Â | |
Yes | 18 (60%) | 6 (55%) | 12 (63%) |
Median Gleason score1 (range) | 9 (8–10) |  |  |